Videos

Yan Leyfman, MD, shared key clinical and practice-shaping insights related to cellular therapy from the 2026 Tandem Meetings.

Seth M. Pollack, MD, discussed how the ECOG-ACRIN EA7222 trial could establish doxorubicin/pembrolizumab as the new frontline standard for undifferentiated pleomorphic sarcoma.

Suzann Duan, PhD, anticipates the release of a paper she coauthored exploring the role of Hedgehog signaling in NETs, as well as within the aging landscape.

Charlotte Ivy Rivers, MD, explored the impact of updated WHO criteria and functional imaging, such as DOTATATE-PET, on the diagnosis and treatment of patients with CNS tumors.

Panelists analyze comparative real-world data from the French DESCAR-T registry evaluating axicabtagene ciloleucel and lisocabtagene maraleucel in second-line relapsed/refractory LBCL. Faculty consider distinctions in toxicity profiles along with selection bias, vein-to-vein time, patient frailty, and whether certain patients may preferentially benefit from one CAR T product over another in routine second-line practice.

Panelists discuss how complete referral information and evolving outpatient pathways (including shortened post-infusion monitoring requirements) can improve coordination, reduce logistical burden, and maintain safe follow-up.

Experts discuss the evolving role of BTK inhibitors and venetoclax in treatment regimens, emphasizing the need for personalized therapy durations.

Panelists discuss how transparent counseling on expected benefits, early-onset toxicities, and practical logistics (travel, caregiver needs, support resources) helps patients make confident decisions about CAR T.

Panelists examine real-world comparative data from the French DESCAR-T registry and REALYSA cohort evaluating second-line axicabtagene ciloleucel versus standard-of-care salvage therapy in early relapsed/refractory DLBCL. The discussion highlights the event-free survival with CAR T-cell therapy (1-year EFS 46% vs 16% in SOC). Faculty also discuss the impact of third-line CAR T use in the SOC arm and what these real-world registry data mean for routine second-line treatment decision-making.

Experts discuss the evolving role of BTK inhibitors and venetoclax in treatment regimens, emphasizing the need for personalized therapy durations.

AI-based models must be trained on data derived from diverse patient populations to eliminate potential bias in the context of palliative care.

Sunil W. Dutta, MD, discussed why clinical follow-up remains an essential soft skill for radiation oncologists in an increasingly automated field.

Vanessa Almendro Navarro, PhD, MBA, outlined what she hopes to accomplish in her new role as chief commercialization officer at City of Hope.

A phase 2 trial will determine whether subcutaneous blinatumomab can offer benefit to a patient population with no other treatment options.

Findings presented at the 2026 Tandem Meetings showed that an accelerated immune constitution of donor-derived CD4-positive T cells was observed with TRX103.

According to Emese Zsiros, MD, PhD, FACOG, the pembrolizumab regimen yields favorable responses and survival in this PROC population.

Further follow-up is necessary to see if AZD0120 may be preferentially used as a treatment for patients with relapsed/refractory multiple myeloma.

Emese Zsiros, MD, PhD, FACOG, spoke about the newly approved pembrolizumab regimen in PD-L1–expressing, pretreated platinum-resistant gynecologic cancers.

J. Isabelle Choi, MD, discussed proton and photon therapy for locoregional recurrences, emphasizing advanced IMRT/VMAT techniques and CTV delineation.

Diane Simeone, MD, detailed how the PRECEDE Consortium utilizes standardized data sharing and high-risk screening to identify stage I pancreatic cancer.

In a presentation at the 2026 ACRO Summit, Pranshu Mohindra, MD, reviewed the treatment planning process for hypofractionated radiation in lung cancer.

Irtiza N. Sheikh, DO, hopes liso-cel accessibility increases in non-clinical trial settings and is considered for use earlier in the LBCL treatment course.

Diane Simeone, MD, highlights the necessity of a collaborative approach to pancreatic cancer screening, similar to trends across multiple disease states.

Sunil Dutta, MD, discusses integrating FAST-Forward and PRIME II trial data to personalize breast cancer treatment and sequencing radiation with ADCs.

Seth M. Pollack, MD, discusses new strategies for converting immune-cold tumors, including the role of TLR4 agonists and IL-12–producing viral agents.

Vanessa Almendro-Navarro, PhD, MBA, outlined her experience as a research fellow and how her clinical work may impact her new role at City of Hope.

Panelists discuss how early financial navigation and proactive payer coordination can mitigate insurance delays and out-of-pocket burdens that commonly derail CAR T access.

Experts discuss the complexities of treatment regimens for CLL, focusing on MRD's role and the impact on patient outcomes.

Panelists discuss how clearer communication and streamlined referral workflows (including dedicated navigation/support roles) can reduce uncertainty around scheduling, manufacturing timelines, and treatment capacity.

Experts discuss the complexities of treatment regimens for CLL, focusing on MRD's role and the impact on patient outcomes.